Featured Research

from universities, journals, and other organizations

Tumors may respond to extreme and moderate heat

Date:
March 12, 2010
Source:
American Association for Cancer Research
Summary:
Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research.

Aided by ultrasound guidance, treating tumors with extreme heat or moderate heat may provide a possible therapeutic option, according to early research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held March 7-10, 2010.

"Low temperature controlled hyperthermia and high temperature treatments are beneficial in curing both malignant and benign tumors using minimally invasive and noninvasive ultrasound techniques," said Osama M. Al-Bataineh, Ph.D., an assistant professor in biomedical engineering at the Hashemite University in Jordan.

Hyperthermia has previously been shown to increase radiation damage to cancerous tissue and prevent subsequent tissue repair. It has further been shown to enhance chemotherapy and immunotherapy treatments by changing the microcirculation and blood vessel permeability properties of a tumor.

Al-Bataineh and colleagues performed the following laboratory experiments.

Using magnetic resonance imaging (MRI) guidance, they were able to maintain desired temperature levels of 43 degrees Celsius for 30 minutes, which is considered the optimal dose to cause the required biological effect for hyperthermia treatment.

In a related experiment, high temperature (greater than 50 degrees Celsius) for between one to two minutes caused permanent tissue damage to the prostate tumor. High temperature treatment appeared to induce necrosis, or cell death.

Al-Bataineh said both extreme and moderate heat appear to have a clear effect on the tumor's cellular structure, but further research would need to be done before any studies are conducted in humans.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Tumors may respond to extreme and moderate heat." ScienceDaily. ScienceDaily, 12 March 2010. <www.sciencedaily.com/releases/2010/03/100311074129.htm>.
American Association for Cancer Research. (2010, March 12). Tumors may respond to extreme and moderate heat. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2010/03/100311074129.htm
American Association for Cancer Research. "Tumors may respond to extreme and moderate heat." ScienceDaily. www.sciencedaily.com/releases/2010/03/100311074129.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins